Cat. No. | Product name | CAS No. |
DCC5397 |
Veledimex
Activator for Proprietary Gene Therapy Promoter System |
1093130-72-3 |
DCC5398 |
Venlafaxine
Serotonin-norepinephrine reuptake inhibitor (SNRI); Antidepressant |
93413-69-5 |
DCC5399 |
Ver-246608
Novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupting Warburg metabolism and inducing context-dependent cytostasis in cancer cells |
1684386-71-7 |
DCC5400 |
veratramine Hydrochloride
Antitumor agent |
1258005-82-1 |
DCC5401 |
Veratridine
Natural Janus-Faced Modulator of Voltage-Gated Sodium Ion Channels, acting on the channel as either an agonist or antagonist depending on the nature of the electrophysiological stimulation protocol |
71-62-5 |
DCC5402 |
Verminoside
Natural anti-inflammatory and antioxidant agent, inhibiting both iNOS expression and NO release in the LPS-induced J774.A1 macrophage cell line, enhancing protein expression levels of PARP-1 and p53, and attenuating intracellular ROS and stress (oxidative |
50932-19-9 |
DCC5403 |
Vernakalant
Novel blocker of atrial potassium channels |
794466-70-9 |
DCC5404 |
Vernolepin
Natural Reversible Plant Growth Inhibitor |
18542-37-5 |
DCC5405 |
Verticilide
Natural insect ryanodine receptor (RyR) antagonist |
693778-57-3 |
DCC5406 |
Verticillin A
Apoptosis inducer, inhibiting Leiomyosarcoma and Malignant peripheral nerve sheath tumor growth |
889640-30-6 |
DCC5407 |
Vesamicol Hydrochloride
Potent inhibitor of acetylcholine transport |
22232-64-0 |
DCC5408 |
Vesiculopolin B
Novel anti-vesiculoviral agent, inhibiting transcription initiation of vesiculoviruses |
|
DCC5409 |
Vezf1-in-t4
Novel Inhibitor of the Pro-Angiogenic Activity of the Zinc Finger Transcription Factor Vezf1 |
|
DCC5410 |
Vhl-hif1α Inhibitor-tg0
The first sub-micromolar inhibitor of the VHL-HIF1α interaction |
|
DCC5411 |
Vibsanin A
Natural protein kinase C (PKC) activator and HSP90 inhibitor, sensitizing human acute myeloid leukemia cells to tyrosine kinase inhibitor-induced myeloid differentiation via activation of PKC and upregulation of Lyn |
72506-14-0 |
DCC5412 |
Vicagrel
Clopidogrel analog as an antiplatelet agent |
1314081-53-2 |
DCC5413 |
Vidarabine Monohydrate
Broad spectrum antibiotic, inhibiting adenylyl cyclase type 5 (AC5) and protecting against chronic coronary artery occlusion (CAO) |
24356-66-9 |
DCC5414 |
Vilanterol
Selective long-acting beta2-adrenergic agonist (LABA) with inherent 24-hour activity for once daily treatment of COPD and asthma |
503068-34-6 |
DCC5415 |
Vincamine V2a
Novel antagonist against hypocretin (orexin) receptor 2, significantly preventing acute morphine-conditioned place preference (CPP) and stress-induced reinstatement of extinguished morphine-CPP in mouse models of opioid reward and relapse |
|
DCC5416 |
Vincapusine
Natural inhibitor of 3C-like protease (3CLpro), targeting SARS-CoV-2 3CLpro, SARS-CoV 3CLpro and MERS-CoV 3CLpro |
80248-97-1 |
DCC5417 |
Vincetoxicoside A
Natural antimicrobial, antioxidant, and anti-inflammator agent |
18016-58-5 |
DCC5418 |
Virodhamine Trifluoroacetate
Endogenous cannabinoid receptor mixed agonist/antagonist, being a full agonist at GPR55 and CB2 and partial agonist/antagonist at CB1 |
1415264-56-0 |
DCC5419 |
Vitexin 4"-o-glucoside
Natural inhibitor of ST2 (IL1RL1) |
178468-00-3 |
DCC5420 |
Viviren
Coelenterazine analog for bioluminescence imaging (BLI) |
|
DCC5421 |
Vmy-1-101
Fluorescent cyclin-dependent kinase inhibitor, blocking the proliferation of human breast cancer cells |
1209002-42-5 |
DCC5422 |
vmy-2-95
Novel and selective desensitizer of |
1434047-61-6 |
DCC5423 |
Setmelanotide Tfa Salt
Featured
Novel highly-selective melanocortin-4 receptor (MC4R) agonist, increasing resting energy expenditure in obese individuals |
920014-72-8 |
DCC5424 |
Voa Analog 19
Novel potent VEGFR2 modulator, exhibiting increased antiangiogenic potency than voacangine against VEGF-induced VEGFR2 phosphorylation without cytotoxic effects, resulting in significant tumor cell death in a mouse xenograft model |
|
DCC5425 |
Voclosporin
Novel calcineurin inhibitor and immunosuppressive agent |
515814-00-3 |
DCC5426 |
Vonoprazan Fumurate
Novel potassium-competitive acid blocker |
881681-01-2 |
DCC5427 |
Vpc-00628
Novel potent and highly selective type-II inhibitor of p38α/β, targeting an inactive state of the kinases induced by a unique folded P-loop conformation |
|
DCC5428 |
Vpc-13163
Potent Antiandrogen, Targeting the BF3 Site of the Androgen Receptor and Inhibiting Enzalutamide-Resistant Prostate Cancer |
6637-10-1 |
DCC5429 |
Vpc-16606
Novel potent and selective inhibitor of ERα-dependent cell growth and gene expression, preventing the interaction between ERα-LBD and SRC-3 fusion proteins in a dose-dependent manner |
2027540-49-2 |
DCC5430 |
Vpc24191
S1P1/S1P3 receptor agonist |
799268-83-0 |
DCC5431 |
Vpc-3033
Novel Androgen Receptor Antagonist, inhibiting the LNCaP cell line as well as cell lines with wild-type androgen receptor |
110763-24-1 |
DCC5432 |
Vpc44116
Competitive S1P1/3 antagonist, increasing capillary permeability as measured by Evans blue dye leakage in mouse lung tissue |
1161429-70-4 |
DCC5433 |
Vrt-325
Corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant |
815592-21-3 |
DCC5434 |
Vrv-pl-viiia Inhibitor 5m
Inhibitor of the catalytic activity of VRV-PL-VIIIa, strongly inhibiting the hemolysis of red blood cells and VRV-PL-VIIIa-induced myotoxicity and lung hemorrhage in mice |
|
DCC5435 |
Vrx-480773
Novel Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) |
|
DCC5436 |
Vsw1198
Novel inhibitor of geranylgeranyl diphosphate synthase (GGDPS) |
|
DCC5437 |
Vswrapta
Novel Promoter of Neuronal Branching Via Transcellular Activation of the Focal Adhesion Kinase (FAK) and the ERK1/2 Signaling Pathway In Vitro |
2229829-30-3 |
DCC5438 |
Vt-me6
Sphingosine kinase (SphK) inhibitor, having modest SphK2-selectivity |
1353880-00-8 |
DCC5439 |
Vtx-2337 Analog-1
Novel selective agonist of TLR8 |
|
DCC5440 |
Vu0034403
Novel non-MPEP site metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs) |
358360-83-5 |
DCC5441 |
Vu0160573
Selective modulator of G protein-coupled inward rectifier K (GIRK) |
488745-62-6 |
DCC5442 |
Vu0184670
Allosteric modulator of the M1 muscarinic receptor |
1135241-95-0 |
DCC5443 |
vu0360173
Novel Positive Allosteric Modulator (PAM) of the Metabotropic Glutamate Receptor 5 (mGlu5) |
1445948-86-6 |
DCC5444 |
Vu0361747
Novel Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5, Revealing Chemical and Functional Diversity and In Vivo Activity in Rat Behavioral Models of Anxiolytic and Antipsychotic Activity |
1309976-66-6 |
DCC5445 |
Vu0364289
Potent and specific PAM for the rat mGluR5 receptor |
1242443-29-3 |
DCC5446 |
Vu0366058
Potent noncompetitive antagonist of Metabotropic_glutamate_receptor_5>metabotropic glutamate receptor 5 (mGlu5) |
1369344-82-0 |
DCC5447 |
Vu0366248
Featured
VU0366248 is a mGlu5 negative allosteric modulator. |
1243310-20-4 |
DCC5448 |
vu0403602
Novel Positive Allosteric Modulator (PAM) of the Metabotropic Glutamate Receptor 5 (mGlu5) |
1403771-22-1 |
DCC5449 |
Vu0404251
Highly potent non-MPEP site metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulator (PAM) |
1276013-77-4 |
DCC5450 |
Vu0409775
Muscarinic antagonist; inhibiting ACh-induced Ca(2+) responses at rat M(1-5) receptor subtypes |
|
DCC5451 |
Vu0410150
Novel positive allosteric modulator (PAM) of mGlu4 |
1296731-74-2 |
DCC5452 |
Vu0413144
Allosteric modulator of the M2/5 muscarinic acetylcholine receptor |
|
DCC5453 |
vu0415248
Highly M1-selective antagonist |
1359087-83-4 |
DCC5454 |
Vu0415371
Novel M4 muscarinic acetylcholine receptor modulator |
|
DCC5455 |
Vu0415374
Novel mGlu4 positive allosteric modulator (PAM) |
1266338-03-7 |
DCC5456 |
Vu0431316
Novel negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety |
1620203-63-5 |
DCC5457 |
vu0448350-1
Highly selective muscarinic M1 PAM |
1418201-75-8 |
DCC5458 |
vu0452865
Selective orthosteric M1 antagonist |
1392442-12-4 |
DCC5459 |
Vu0453379
Novel, CNS Penetrant Glucagon-Like Peptide 1 Receptor (GLP-1R) Positive Allosteric Modulator (PAM) |
1638646-27-1 |
DCC5460 |
Vu0462054
Novel potent and selective metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulator (PAM) |
|
DCC5461 |
vu0463841
Potent and selective mGlu5 negative allosteric modulator (NAM) |
1439095-16-5 |
DCC5462 |
Vu0477886
Novel potent mGlu4 PAM with an attractive DMPK profile, and robust efficacy in preclinical Parkinsons disease model, haloperidol-induced catalepsy (HIC) |
|
DCC5463 |
Vu0486321
mGlu1 positive allosteric modulator (PAM) |
1816301-67-3 |
DCC5464 |
Vu0487836
Novel cyclooxygenase-1 (COX-1)-selective inhibitor |
1632301-78-0 |
DCC5465 |
vu573 Hydrochloride
Novel modulator of mammalian inward rectifying potassium (Kir) channels |
1049717-96-5 |
DCC5466 |
Vu6001192
Novel selective negative allosteric modulator (NAM) of metabotropic glutamate receptor subtype 2 |
1821325-29-4 |
DCC5467 |
Vu6004909
Novel potent and highly selective mGlu1 PAM (22nM), reducing striatal DA release in vivo and displaying antipsychotic efficacy |
|
DCC5468 |
Vu6007705
Novel Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) |
2222737-18-8 |
DCC5469 |
Vu6008555
Novel Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) |
2222737-14-4 |
DCC5470 |
Vu6009453
Novel M4 positive allosteric modulator (PAM) |
2148929-11-5 |
DCC5471 |
Vu6009833
Novel CNS penetrant pan-muscarinic antagonist |
|
DCC5472 |
Vu6013429
Novel PAM of Group III (mGlu4/6/7/8) mGlu receptors |
|
DCC5473 |
Vu6017587
Novel selective mGlu3 NAM, showing efficacy in tail suspension, elevating zero maze and marble burying, suggesting selective inhibition of mGlu3 affords anxiolytic-like and antidepressant-like phenotypes in mice |
|
DCC5474 |
Vu6027459
First-in-class selective mGlu7 positive allosteric modulator (PAM), displaying CNS penetration in both mice (Kp = 2.74) and rats (Kp= 4.78) |
|
DCC5475 |
Vuf 5681 Dihydrobromide
Potent histamine H3 receptor silent antagonist |
639089-06-8 |
DCC5476 |
Vuf10132
Novel full inverse agonist at CXCR3 N3.35A |
1037732-88-9 |
DCC5477 |
vuf10148
Potent H4R ligand |
1001065-53-7 |
DCC5478 |
Vuf10166 Hydrochloride
Novel potent ligand at 5-HT3A and 5-HT3AB receptors with different activities |
55686-37-8 |
DCC5479 |
Vuf10497
Featured
VUF10497 is a potent histamine H4 receptor (H4R) inverse agonist with anti-inflammatory activity. |
1080623-12-6 |
DCC5480 |
Vuf10499
Potent human H4 receptor inverse agonist |
1080623-05-7 |
DCC5481 |
Vuf10558
Highly Potent Human Histamine H4 Receptor Inverse Agonist |
1166378-39-7 |
DCC5482 |
Vuf11211
Potent CXCR3 Antagonist, extending from the minor pocket into the major pocket of the transmembrane domains and binding between residues in helices 1 (Y1.39), 2 (W2.60), 3 (F3.32), 4 (D4.60), 6 (Y6.51), and 7 (S7.39, Y7.43) |
906556-51-2 |
DCC5483 |
Vuf11222
First reported nonpeptidomimetic agonist on The G protein-coupled chemokine receptor CXCR3 |
1414376-84-3 |
DCC5484 |
vuf14480
Partial agonist in hH 4 R-mediated G protein signalling and β-arrestin2 recruitment, bounding covalently to the hH4R |
1605304-31-1 |
DCC5485 |
Vuf14738
Novel robust and fatigue-resistant photoswitchable GPCR antagonist |
2223027-70-9 |
DCC5486 |
Vuf14862
Novel robust and fatigue-resistant photoswitchable GPCR antagonist |
2223023-78-5 |
DCC5487 |
Vuf15259
Novel inhibitor of Hbp secretion, activating σE stress, impairing Hbp secretion and decreasing the abundance of OMPs, consistent with impaired BAM function |
|
DCC5488 |
Vuf15888
Novel photoswitchable modulator of the CXCR3 chemokine receptor |
|
DCC5489 |
Vuf16216
Novel CXCR3 ligand, photoswitching from antagonism to agonism |
|
DCC5490 |
Vuf16620
Novel photoswitchable modulator of the CXCR3 chemokine receptor |
|
DCC5491 |
vuf5228
Histamine H3 receptor antagonist |
785767-25-1 |
DCC5492 |
Vuf5391
H3R inverse agonist |
|
DCC5493 |
vuf5455
Adenosine A3 receptor (A3AR) allosteric modulator |
390817-85-3 |
DCC5494 |
Vuf5834
Novel full inverse agonist at CXCR3 N3.35A |
860002-95-5 |
DCC5495 |
Vuf-6884
Full agonist of hH4R with ~300-fold selectivity over hH3R and hH2R, but showing potent inverse agonistic activity at hH1R |
3455-10-5 |
DCC5496 |
Vuf-8430
Potent histamine H4 receptor full agonist |
98021-17-1 |
DCC5497 |
Vuf8504
Allosteric modulator of A3 adenosine receptors |
112575-50-5 |
DCC5498 |
Biricodar(Vx-710)
Featured
Biricodar (VX-710) is a modulator of P-glycoprotein and MRP-1; shows effective chemosensitizing activity in multidrug resistant cells. |
159997-94-1 |
DCC5499 |
Vzmc013
Novel Probe of Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity |
|
DCC5500 |
w-13 Hydrochloride
Featured
W-13 hydrochloride is a calmodulin antagonist. W-13 hydrochloride can inhibit Tamoxifen (HY-13757A)-resistant human breast cancer cell growth. |
88519-57-7 |
DCC5501 |
w-5 Hydrochloride
Calmodulin antagonist, inhibiting Ca2+/calmodulin-regulated enzyme activities |
61714-25-8 |
DCC5502 |
waladin1
Mixed competitive/noncompetitive inhibitor of |
1170611-39-8 |
DCC5503 |
Wallichoside
Nocel inhibitor of BMI1 promoter activity, decreasing BMI1 protein levels in HCT116 human colon carcinoma cells, significantly reducing levels of the CSC biomarker epithelial cell adhesion molecule and diminishing the self-renewal capability of CSCs |
31087-88-4 |
DCC5504 |
Way103
Very late adhesion molecule 4 (VLA-4) antagonist, inhibiting VLA-4/VCAM-1 ligation as a means of modulating eosinophil functions beyond its action on cell adhesion and migration |
|
DCC5505 |
Way-123783
SGLT2 inhibitor |
152595-59-0 |
DCC5506 |
way-133537
ATP-sensitive potassium channel opener |
177476-74-3 |
DCC5507 |
Way-151693
Inhibitor of human collagenase-3 (MMP-13) |
206551-25-9 |
DCC5508 |
Way-170523
Potent and selective inhibitor of matrix metalloprotease MMP-13 (Collagenase-3) |
307002-73-9 |
DCC5509 |
Way-171230
Inhibitor of matrix metalloproteinase-1 (MMP-1) |
|
DCC5510 |
Way-260022
Potent and Selective Inhibitor of the Norepinephrine Transporter |
850692-43-2 |
DCC5511 |
Way-316606 Hydrochloride
Secreted frizzled-related protein-1 (sFRP-1) modulaitor |
1781835-02-6 |
DCC5512 |
Wb-308
Novel inhibitor of The epidermal growth factor receptor (EGFR), decreasing NSCLC cell proliferation and colony formation, by causing G2/M arrest and apoptosis. |
1373764-87-4 |
DCC5513 |
Wb4-24
Non-peptide GLP-1 receptor agonist, blocking inflammatory nociception by stimulating β-endorphin release from spinal microglia |
|
DCC5514 |
Wck5153
Novel Inhibitor of PBP2, Showing Potent β-Lactam Enhancer Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones |
1436862-38-2 |
DCC5515 |
We-14 Tfa Salt
Highly conserved neuropeptide derived from Chromogranin A (Parathyroid Secretory Protein 1) |
115136-18-0 |
DCC5516 |
Web2347
Novel very potent and long acting hetrazepinoic PAF-antagonist |
114800-19-0 |
DCC5517 |
Wen05-03
Novel inhibitor of type III secretion system ATPase EscN from enteropathogenic Eecherichia coli |
|
DCC5518 |
Wfq-228
Novel fluoroquinolone antibiotic with potent antimicrobial activity, showing the potential to overcome major drug resistance; its antimicrobial activity was less affected by both pump-mediated efflux and QRDR mutations in P. aeruginosa compared with LVX a |
|
DCC5519 |
Whz-04
Novel Anti-malarial Plasmodium-Selective Proteasome Inhibitor |
|
DCC5520 |
Win-35428
Dopamine reuptake inhibitor, also having some SERT affinity |
50370-56-4 |
DCC5521 |
Win-64338
B2 bradykinin receptor antagonist |
151039-63-3 |
DCC5522 |
Withangulatin A
Natural potent antitumoragent, targeting sarco/endoplasmic reticulum calcium-ATPase (SERCA)2 |
120824-03-5 |
DCC5523 |
Wj35435
Novel dual inhibitor of histone deacetylase and topoisomerase I |
1620054-84-3 |
DCC5524 |
Wjd008
Novel potent dual inhibitor of phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR), preventing PI3K signaling and inhibiting the proliferation of transformed cells with oncogenic PI3K mutant |
1309087-83-9 |
DCC5525 |
Wms-1410
Novel GluN2B-specific NMDAR antagonist, completely preventing the decrease in insulin secretion of about 32 % provoked by a 24-h-treatment with NMDA/glycine, eliminating NMDA-induced changes in the oxidation status of the islet cells and elevating the sen |
|
DCC5526 |
Wms-2539
Potent uncompetitive NMDA receptor antagonist |
|
DCC5527 |
Wn1316
Unique neuroprotectant against oxidative injury, being a highly promising remedy for the treatment of amyotrophic lateral sclerosis (ALS) |
1356959-71-1 |
DCC5528 |
Wnk-in-3
Novel Allosteric WNK Kinase Inhibitor |
853298-47-2 |
DCC5529 |
Wnt/hh-in-1
Novel potent dual inhibitor of Wnt and hedgehog signalings, blocking porcupine and smoothened |
|
DCC5530 |
Wny0824
Novel dual BRD4 and PLK1 inhibitor (IC 50 values of 109 and 22 nM, respectively), showing strong antiproliferative activity against cancer cells |
|
DCC5531 |
Wo-459
Novel GPR52 agonist, dose-dependently inducing elevation of intracellular cAMP in HEK293/GPR52 cells |
1313195-84-4 |
DCC5532 |
Wp1193
Novel inhibitor of the JAK2/STAT3 pathway |
951693-87-1 |
DCC5533 |
Wp-871 Monohydrate
Main active metabolite of tazanolast, inhibiting dose-dependently compound 48/80-induced histamine release from rat peritoneal mast cells |
1184521-48-9 |
DCC5534 |
Wqe-134
Novel Dual Inhibitor of Nitric Oxide and Prostaglandin E2 Production |
|
DCC5535 |
Wr99210
Potent inhibitor of Plasmodium falciparum dihydrofolate reductase (DHFR) |
47326-86-3 |
DCC5536 |
Wrr-286
Novel potent inhibitor of Schistosoma mansoni cathepsin B1 (SmCB1) with IC50 ~0.6 nM |
|
DCC5537 |
Wrr-391
Novel potent inhibitor of Schistosoma mansoni cathepsin B1 (SmCB1) with IC50 ~0.2 nM |
|
DCC5538 |
wrr-483
Analog of K11777; Irriversible effective cysteine protease inhibitor with trypanocidal activity in cell culture and animal model with comparable efficacy to K11777. |
1076089-14-9 |
DCC5539 |
Ws-47-js03
Novel potent RET kinase inhibitor with >500-fold selectivity against KDR (Kinase insert Domain Receptor) in cellular assays |
|
DCC5540 |
Ws-691
Novel highly potent and orally active ABCB1 modulator capable of overcoming MDR, stabilizing ABCB1 by directly binding to ABCB1, stimulating the activity of ABCB1 ATPase without inhibitory activity against CYP3A4, increasing the sensitivity of SW620/Ad300 |
|
DCC5541 |
Wsj-557
Novel xanthine oxidase inhibitor |
|
DCC5542 |
Wu-07047
Simplified analog of the selective Gαq/11 inhibitor YM-25489 |
1702378-78-6 |
DCC5543 |
Wwl123
Novel α/ß-hydrolase domain 6 (ABHD6) inhibitor |
1338574-83-6 |
DCC5544 |
Wx-671
Novel urokinase inhibitor |
590368-25-2 |
DCC5545 |
Wye-687 Dihydrochloride
Potent, ATP-competitive inhibitor of mammalian target of rapamycin (mTOR) |
1062161-90-3 |
DCC5546 |
Wyk431
Potent inhibitor of proliferation activity against a broad spectrum of human cancer cell lines, induces G2/M phase arrest and apoptosis through the PI3K/Akt pathway |
|
DCC5547 |
Xanthoangelol
Natural antibacterial agent against Gram-positive bacterial pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus faecium and Enterococcus faecalis |
62949-76-2 |
DCC5548 |
Xantholipin
Antibiotic, exhibiting strong antibacterial activities and showing potent cytotoxicity, inhibiting HSP47 gene expression produced by Streptomyces sp |
|
DCC5549 |
Xantholipin B
Novel antibiotic, showing 3- to 10-fold greater cytotoxicity than Xantholipin against a select panel of human cancer cell lines, demonstrating powerful antimicrobial activity against both Gram-positive bacteria and fungi |
|
DCC5550 |
XAX-162
Quantity (mg or Unit) Unit Price ($/mg or $/Unit) Final Price 100 $26.55 Total: $2,655.00 50 $30.68 Total: $1,534.00 25 $35.99 Total: $899.75 10 $42.48 Total: $424.80 5 $50.15 Total: $250.75 |
|
DCC5551 |
xc-409
Novel PKM2 activator |
931066-63-6 |
DCC5552 |
Xen103
Potent and Selective Stearoyl-CoA Desaturase-1 Inhibitor |
840489-44-3 |
DCC5553 |
Xie18-6
Novel INK4C inhibitor, specifically blocking the bioactivity of p18 protein and promoting human and murine hematopoietic stem cell ex vivo expansion |
1286862-52-9 |
DCC5554 |
Xist Ligand X1
Novel non-coding RNA prototype Xist ligand, specifically binding the RepA motif of Xist, reducing the conformational space of RepA, displacing cognate interacting protein factors (PRC2 and SPEN), suppressing histone H3K27 trimethylation, and blocking init |
|
DCC5555 |
Xl-13n
Novel dual inhibitor of AF9 and ENL YEATS domains |
|
DCC5556 |
Xl-147
Novel Potent Pan-Filovirus Inhibitor, showing potent inhibition against infectious EBOV Zaire (0.09 μM) and MARV (0.64 μM) |
|
DCC5557 |
Xl-418
Novel Akt1/2 inhibitor |
1056474-52-2 |
DCC5558 |
Xr9051 Hydrochloride
Potent modulator of P-glycoprotein-mediated multidrug resistance (MDR), inhibiting the binding of cytotoxics to P-glycoprotein |
180422-22-4 |
DCC5559 |
Xstax-vhll
Novel selective β-catenin degrader |
|
DCC5560 |
Xylariamide A
Carbonic anhydrase inhibitor; Fungal metabolite |
853259-88-8 |
DCC5561 |
Xylarianaphthol-1
Novel activator of p21 promoter in a p53-independent manner |
1620084-30-1 |
DCC5562 |
Y08624
Novel TRIM24/BRPF1 dual inhibitor with IC 50 values of 0.98 and 1.16 μM, respectively |
|
DCC5563 |
Y2 Antagonist 36
Novel non-peptidic highly potent, soluble and selective NPY Y2 antagonist |
1185845-15-1 |
DCC5564 |
Y2-antagonist-2
Novel, selective, soluble non-peptidic NPY Y2 receptor antagonist with enhanced CNS exposure |
1262495-12-4 |
DCC5565 |
Y-39983 Dihydrochloride
Selective Rho-associated kinase (ROCK) inhibitor |
173897-44-4 |
DCC5566 |
Yak037
Tamoxifen-analog that Suppresses Glial L-Glutamate Transport Activity without Interaction with Estrogen_receptor>Estrogen Receptors |
1177261-99-2 |
DCC5567 |
Ycw-e11
Novel Inhibitor of Antiapoptotic Bcl-2 Family Proteins |
1519043-97-0 |
DCC5568 |
Yh18968
Novel GPR119 Agonist, improving glucose tolerance and augmenting the glucose lowering effect as well as the plasma level of active GLP-1 in normal mice in combination treatment with a dipeptidyl peptidase 4 (DPP-4) inhibitor |
1632498-56-6 |
DCC5569 |
Yh-gka
Novel glucokinase activator, significantlt decreasing in blood glucose levels with no adverse effects on serum lipids or body weight |
|
DCC5570 |
Yk-5-252
Novel dual action combretastatin A-4 (CA-4) prodrug, releasing CA-4 through a disulfide bond cleavage mechanism and containing a near-infrared (NIR) fluorophore |
|
DCC5571 |
Ykl-05-093
Novel salt inducible kinase (SIK) inhibitor, increasing bone formation and bone mass |
2172616-44-1 |
DCC5572 |
Ylt192
Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy |
1246566-47-1 |
DCC5573 |
Ylt205
Novel Inducer of Apoptosis in Human Colorectal Cells via Mitochondrial Apoptosis Pathway, Inhibiting Tumor Growth |
1316196-63-0 |
DCC5574 |
Ym-17690
Novel non-analogous leukotriene agonist |
108806-41-3 |
DCC5575 |
ym-201627
Selective growth inhibitor of endothelial cells |
326851-54-1 |
DCC5576 |
Ym-244769
Featured
YM-244769 is a potent, selective and orally active Na+/Ca2+ exchanger (NCX) inhibitor. YM-244769 preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca2+ entry mode), with IC50s of 18 nM and 50 nM, respectively. YM-244769 efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 can also increase urine volume and urinary excretion of electrolytes in mice. |
838819-70-8 |
DCC5577 |
ym-298198 Dihydrochloride
Potent and selective mGLu1 antagonist |
299901-50-1 |
DCC5578 |
Ym-90k
Novel AMPA receptor antagonist |
143151-35-3 |
DCC5579 |
Yml220
Potent and selective microbicidal agent against wild type (wt) HIV-1, NNRTI-, NRTI-, PRI-resistant mutants |
|
DCC5580 |
Ynt-1310
Water-soluble analog of YNT-707, acting as a potent orexin 1 receptor (OX1R) antagonist |
|
DCC5581 |
Ynt-707
Novel potent orexin 1 receptor (OX1R) antagonist |
|
DCC5582 |
Yoyo-1
DNA-intercalating dye as sensitive amyloid probe |
143413-85-8 |
DCC5583 |
Ysy01a
Novel Proteasome Inhibitor, Enhancing Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells, inducing cell cycle arrest on G2 phase in MCF-7 cells via ERα and PI3K/Akt pathways |
|
DCC5584 |
Yt-146
Selective A 2A receptor agonist |
90596-75-1 |
DCC5585 |
Yu2534342249
Novel γ-lactam pyrazolidinone, targeting penicillin-binding proteins (PBPs) and incorporating a siderophore moiety to facilitate uptake into the periplasm, being effective against multidrug-resistant gram-negative Bacilli |
|
DCC5586 |
Yw2065
Novel inhibitor of Wnt signaling by stabilizing Axin-1, a scaffolding protein that regulates proteasome degradation of β-catenin |
2131223-85-1 |
DCC5587 |
Yycg Inhibitor 16
Novel YycG inhibitor, inhibiting planktonic cells of E. faecalis, including the vancomycin- or linezolid-resistant strains |
506429-34-1 |
DCC5588 |
Yycg Inhibitor 62
Novel YycG inhibitor, significantly inhibited biofilm formation in static and dynamic conditions |
|
DCC5589 |
Yz-2-90
Novel activator of JNK, binding directly to microtubules, inducing ERK-mediated mitotic arrest and subsequent apoptosis |
1159013-10-1 |
DCC5590 |
Z118332870
Novel first-in-class inhibitor of BRD4 and EGFR kinase |
1223377-83-0 |
DCC5591 |
Z1241145220
Novel potent ligand of σ2 receptor (K i =7nM) |
|
DCC5592 |
Z1913661252
Novel riboswitch activator, binding ZTP riboswitches, and activating transcription more strongly than ZMP in vitro |
1798713-75-3 |
DCC5593 |
Z4446724338
Novel potent dual σ1/2 ligand (σ1 K i =5nM, σ2 K i =3nM), showing anti-allodynic in a model of neuropathic pain |
2445793-01-9 |
DCC5594 |
Z56965384
Novel USP10 inhibitor |
438607-49-9 |
DCC5595 |
Zarilamide
Inhibitor of the nuclear division in germinating zoospore cysts of Phytophthora capsici via destruction of the microtubule cytoskeleton, and a consequent inhibition of mitosis |
84527-51-5 |
DCC5596 |
Zatosetron
Serotonin 5-HT3 receptor antagonist |
123482-22-4 |